List view / Grid view
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
13 June 2013 | By Roche
Roche announced data from two phase III studies...
15 May 2013 | By Sanofi
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials...
AbbVie has announced the European Commission (EC) has approved an update to the label for HUMIRA® (adalimumab) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). The update adds data demonstrating the long-term clinical benefit of HUMIRA, making it the first and only biologic medication available with…
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
12 July 2011 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials...
